Although kidney outcomes were secondary or exploratory in these CVOTs, the subgroup of participants with T2D and CKD experienced similar relative improvements in kidney outcomes when treated with SGLT2 inhibitors to that documented in the CREDENCE study (55). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.